CN111378000A - Cycloastragenol crystal form F and preparation method thereof - Google Patents
Cycloastragenol crystal form F and preparation method thereof Download PDFInfo
- Publication number
- CN111378000A CN111378000A CN201811644147.9A CN201811644147A CN111378000A CN 111378000 A CN111378000 A CN 111378000A CN 201811644147 A CN201811644147 A CN 201811644147A CN 111378000 A CN111378000 A CN 111378000A
- Authority
- CN
- China
- Prior art keywords
- cycloastragenol
- degrees
- crystal form
- preparation
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of organic chemical medicine preparation, and provides a cycloastragenol crystal form F and a preparation method and application thereof. The crystal form F of the cycloastragenol provided by the invention has higher purity and better chemical stability, the crystal form F has better dissolution and release behaviors when being prepared into a medicinal preparation, and meanwhile, the preparation method of the cycloastragenol provided by the invention is simple, convenient, easy to industrialize and strong in production adaptability.
Description
Technical Field
The invention belongs to the technical field of organic chemical medicine preparation, and particularly relates to a cycloastragenol crystal form F and a preparation method and application thereof.
Background
Astragaloside IV is a representative saponin component of the traditional Chinese medicine radix astragali, and cycloastragenol CAG is a sapogenin of astragaloside IV. Cycloastragenol is a main hydrolysis metabolite of astragaloside in intestinal tracts and a blood-entering component after being absorbed, has relatively small molecular mass and strong lipophilicity, and is beneficial to biomembrane permeation and gastrointestinal tract absorption to achieve better bioavailability. A large number of modern medical researches prove that the astragaloside IV can relieve the injury of ischemia reperfusion brain tissue by enhancing the oxygen free radical scavenging capability of an organism, inhibiting peroxidation, relieving neuron calcium overload and the like. The research of Geron biotechnology company in the United states discovers that CAG has obvious telomerase activation effect, and Revgenetics nutrition and health products company in the United states also proves that CAG is one of the raw materials of functional cosmetics and nutrition food, is the only raw material which can activate telomerase in human cells at present, and is an anti-aging substance with development prospect. The existing commercially available cycloastragenol is tasteless and amorphous white powder, and the structure of the existing commercially available cycloastragenol is shown as a formula 1:
at present, the astragaloside is generally prepared by hydrolyzing astragaloside by a chemical method, but the three-membered ring structure on the astragaloside is unstable, and more byproducts are easily generated. Chinese patent CN104817610A uses sulfuric acid to hydrolyze astragaloside to prepare cycloastragenol, but the reaction requires a high-temperature and high-pressure resistant reaction kettle, and the purification steps of the final product are complex; chinese patent CN103880910A reports that cycloastragenol is prepared by redox method, but its process is relatively complex; in addition, both patent CN105734109A and patent CN105566434A use multiple hydrolases to hydrolyze astragaloside IV in a complex form to prepare cycloastragenol. However, the cycloastragenol prepared by the prior art is amorphous white powder, the chemical stability of the cycloastragenol is poor due to the special structural property of the cycloastragenol, and the change of the conditions in the preparation process can greatly influence the physicochemical property of the cycloastragenol; in addition, the poor dissolution property and the low in vivo bioavailability greatly limit the application, development and popularization of the compound as a medicament. In order to overcome the disadvantages of the existing amorphous cycloastragenol powder, researchers are constantly searching for a series of compounds for preparing cycloastragenol with stable physicochemical properties. It is known that different crystal forms of the same drug may have significant differences in solubility, melting point, density, thermal stability, etc., thereby affecting the stability, homogeneity, bioavailability, therapeutic effect and safety of the drug to varying degrees. However, the research on the related crystal form of the cycloastragenol in the existing literature has not been reported. Therefore, comprehensive and systematic polymorphic form screening is carried out in drug research and development, and the preparation of the compound crystal form with excellent dissolution property, biocompatibility and chemical stability has important significance for expanding the medical application of the cycloastragenol.
Disclosure of Invention
The invention aims to provide a crystal form of cycloastragenol, named as crystal form F, which has high purity and good chemical stability.
The second purpose of the invention is to provide a preparation method of the crystal form F of cycloastragenol, which is simple and convenient in process and suitable for industrial production.
The third purpose of the invention is to provide a pharmaceutical composition containing the crystal form F of cycloxaprid alcohol and application of the crystal form in preparing a medicament for treating diseases.
The specific technical content of the invention is as follows:
in a first aspect of the invention, a crystalline form F of cycloastragenol.
Preferably, the crystal form F of the cycloastragenol has diffraction peaks at 3.17 +/-0.2 degrees, 3.29 +/-0.2 degrees, 6.35 +/-0.2 degrees, 6.61 +/-0.2 degrees, 12.63 +/-0.2 degrees and 13.31 +/-0.2 degrees by using Cu-K α radiation and an X-ray powder diffraction spectrum represented by 2 theta.
Preferably, the crystal form F of cycloastragenol is irradiated by Cu-K α, and the X-ray powder diffraction spectrum of the crystal form F of cycloastragenol has diffraction peaks at 3.17 +/-0.2 degrees, 3.29 +/-0.2 degrees, 4.94 +/-0.2 degrees, 6.35 +/-0.2 degrees, 6.61 +/-0.2 degrees, 12.01 +/-0.2 degrees, 12.63 +/-0.2 degrees, 13.31 +/-0.2 degrees, 14.28 +/-0.2 degrees, 14.93 +/-0.2 degrees, 17.17 +/-0.2 degrees and 18.90 +/-0.2 degrees, which are expressed by 2 theta.
Preferably, the crystal form F of the cycloastragenol is irradiated by Cu-K α, and the X-ray powder diffraction spectrum of the crystal form F of the cycloastragenol is shown in figure 1.
In a second aspect of the invention, a preparation method of a cycloastragenol crystal form F is characterized by comprising the following specific preparation steps:
adding cycloastragenol into methanol, heating and refluxing, filtering while the solution is hot, collecting filtrate, cooling the filtrate, adding n-hexane, sealing with sealing membrane, pricking hole, crystallizing, filtering, collecting solid, and drying to obtain crystalline cycloastragenol.
Preferably, the mass volume ratio of the cycloastragenol to the methanol is 1: 6, g/ml.
Preferably, the volume ratio of the methanol to the n-hexane is 1: 6.
preferably, the heating reflux time is 2-4 h.
Preferably, the temperature of the cooled filtrate is 0-5 ℃.
Preferably, the temperature of the reduced pressure drying is 40-60 ℃.
In a third aspect of the invention, the invention relates to a pharmaceutical composition containing the crystal form F of cycloastragenol and application of the crystal form in preparing a medicament for treating diseases.
A pharmaceutical composition comprising any of the crystalline forms F of cycloastragenol of the invention and other components.
Preferably, the preparation method of the pharmaceutical composition is as follows: the compounds of the present invention are combined with pharmaceutically acceptable solid or liquid carriers and optionally with pharmaceutically acceptable adjuvants and excipients using standard and conventional techniques to prepare useful dosage forms.
Preferably, the pharmaceutical composition comprises spray, tablets, capsules, powder injections, liquid injections, freeze-dried powder injections and other pharmaceutically available dosage forms.
The crystal form F of the cycloastragenol prepared by the invention has the following specific structural representation:
the instrument model is as follows: PANALYTICAL X-RAY POWDER DIFFRACTOMETER
The test method comprises the following steps: filling the ground sample (100mg) in a groove of a glass plate, hanging the plane of the glass plate flush with the surface of the glass plate by a glass slide, placing the sample in a PANalytical X-ray powder diffractometer, using a 40kV and 40mA copper X-ray source, wherein the divergence slit is 1/4 degrees, the anti-divergence slit is 1 degree, the cable-pulling slit is 0.04rad, and the step length is as follows: 0.5s, and a scanning range of 3-50 degrees (2)θ) The scanning speed was 8 °/min. The scan error is typically + -0.2 degrees (2)θ)。
TABLE 1X-ray powder diffraction data of cycloastragenol form F
Compared with the prior art, the crystal form F of the cycloastragenol provided by the invention has higher purity and better chemical stability. In the research, the inventor finds that the change of relevant conditions in the preparation process has great influence on the physicochemical properties of a target product, and the target product is influenced by multiple factors, but through the diligent research of the inventor, the crystal form F can be stably prepared by the method provided by the invention, and the defect that the existing cycloastragenol has unstable physicochemical properties is overcome. Meanwhile, the preparation method of the cycloastragenol crystal form F provided by the invention is simple and convenient, is easy to industrialize, and has strong production adaptability.
Drawings
FIG. 1: an X-ray powder diffraction pattern of cycloastragenol crystal form F.
Detailed Description
The invention is further illustrated by the following examples, which should be properly understood: the examples of the present invention are intended to be illustrative only and not to be limiting, and therefore, the present invention is intended to be simply modified within the scope of the present invention as claimed.
The raw material of the cycloastragenol used in the embodiment of the invention can be a crystal form A prepared by the self, and can also be other raw materials of crude cycloastragenol; the raw material can be prepared by the following method:
adding 20.0g of cycloastragenol into 60mL of absolute ethanol solution, heating to 40 ℃ to completely dissolve the cycloastragenol, filtering the obtained mixed solution, adding 650mL of normal hexane into the filtrate, stirring, slowly cooling to 40 ℃, keeping the temperature, stirring for 30 minutes, keeping the temperature, and standing for 8 hours; cooling to 30 ℃, keeping the temperature and stirring for 40 minutes, keeping the temperature and standing for 10 hours; cooling to 20 ℃, keeping the temperature and stirring for 30 minutes, keeping the temperature and standing for 10 hours; cooling to 10 ℃, keeping the temperature and stirring for 30 minutes, keeping the temperature and standing for 8 hours; and finally, cooling to-10 ℃, continuously preserving heat, stirring for 6 hours, filtering, and vacuum drying at 40 ℃ to obtain the crystal form A of the cycloastragenol.
Example 1
Adding 1g of cycloastragenol into 6ml of methanol to prepare 166mg/ml of cycloastragenol methanol solution, heating to reflux, refluxing for 2-4 h to completely dissolve the cycloastragenol, filtering while hot to obtain filtrate, placing a device for containing the filtrate in an ice water bath, reducing the temperature to 0-5 ℃, adding 36ml of n-hexane, sealing by a sealing film, pricking holes, crystallizing for 2-4 days at the temperature, filtering, collecting solids, and drying under reduced pressure at 50 ℃ to obtain crystalline cycloastragenol, wherein the yield is as follows: 91.3%, HPLC purity: 99.95 percent.
Comparative example 1
Dissolving 5g of cycloastragenol with 200ml of ethyl acetate-ethanol (volume ratio is 5: 1), then placing at-10 ℃ for 24h, crystallizing, filtering and drying to obtain the cycloastragenol monomer compound, wherein the yield is as follows: 62.4%, HPLC purity: 97.04 percent.
Comparative example 2
Adding 10g of cycloastragenol into 450ml of ethanol, adding 0.5g of activated carbon, and heating and refluxing at 90 ℃ for 100 min; filtering, cooling the recrystallization solvent to room temperature, placing in a freezer at 10-25 deg.C, separating out cycloastragenol crystal, filtering, drying to obtain cycloastragenol crystal, and obtaining yield: 83.6%, HPLC purity: 99.16 percent.
Stability test
The specific stability test method refers to a guidance method related to stability investigation in the fourth part of the Chinese pharmacopoeia 2015 edition, the purity detection is performed by an HPLC method, and specific test results are shown in the following table.
TABLE 2 stability test results of crystalline form F of cycloastragenol under light, high temperature and high humidity conditions
Experiments show that the crystal form F of the cycloastragenol prepared by the invention has approximate stability effect, the purity and the appearance of the crystal form F of the cycloastragenol are not obviously changed under the conditions of illumination, high temperature and high humidity, the purity of the crystal form F of the cycloastragenol prepared according to the comparative example 1 and the comparative example 2 is greatly reduced under the same experimental conditions, the impurity content of the crystal form F of the cycloastragenol is obviously increased, and the crystal form F of the cycloastragenol prepared by the invention has better chemical stability compared with the existing cycloastragenol.
Solubility test
The solubility in water and solutions of different pH was determined for the examples and comparative examples, respectively. Respectively measuring 10ml of medium (water, 0.01mol/L HCl solution and phosphate buffer solution with pH of 6.8) into a penicillin bottle, adding excessive medicine, sealing the penicillin bottle, placing the penicillin bottle in a constant-temperature water bath at 25 ℃, stirring for 1 hour, filtering through a 0.45-micrometer filter membrane, respectively measuring absorbance of filtrate at a wavelength of 200nm, and measuring the absorbance of a standard control to calculate the solubility of the penicillin bottle.
TABLE 3 solubility of cycloastragenol form F in different media
Experiments show that the crystal form F of the cycloastragenol prepared by the invention has similar solubility, namely the solubility of the crystal form F of the cycloastragenol prepared by the invention in solutions with different pH values is higher than that of the cycloastragenol prepared according to the comparative examples 1 and 2, and the crystal form F of the cycloastragenol prepared by the invention has excellent solubility.
Claims (10)
1. A crystal form F of cycloastragenol is characterized in that Cu-K α is used for radiation, and the X-ray powder diffraction spectrum of the crystal form F is expressed by 2 theta and has diffraction peaks at 3.17 +/-0.2 degrees, 3.29 +/-0.2 degrees, 6.35 +/-0.2 degrees, 6.61 +/-0.2 degrees, 12.63 +/-0.2 degrees and 13.31 +/-0.2 degrees.
2. Crystalline form F of cycloastragenol according to claim 1, characterized in that, using radiation of Cu-K α, its X-ray powder diffraction spectrum has diffraction peaks expressed in terms of 2 Θ at 3.17 ± 0.2 °, 3.29 ± 0.2 °, 4.94 ± 0.2 °, 6.35 ± 0.2 °, 6.61 ± 0.2 °, 12.01 ± 0.2 °, 12.63 ± 0.2 °, 13.31 ± 0.2 °, 14.28 ± 0.2 °, 14.93 ± 0.2 °, 17.17 ± 0.2 °, 18.90 ± 0.2 °.
3. Crystalline form F of cycloastragenol according to claim 1, having an X-ray powder diffraction spectrum according to figure 1, when irradiated with Cu-K α.
4. A process for the preparation of form F of cycloastragenol according to any one of claims 1 to 3, characterised in that the specific preparation steps comprise: adding cycloastragenol into methanol, heating and refluxing, filtering while the solution is hot, collecting filtrate, cooling the filtrate, adding n-hexane, sealing with sealing membrane, pricking hole, crystallizing, filtering, collecting solid, and drying to obtain crystalline cycloastragenol.
5. The method according to claim 4, wherein the mass-to-volume ratio of cycloastragenol to methanol is 1: 6, g/ml; the volume ratio of the methanol to the n-hexane is 1: 6.
6. the method according to claim 4, wherein the heating and refluxing time is 2 to 4 hours.
7. The method according to claim 4, wherein the temperature of the filtrate after cooling is 0 to 5 ℃.
8. The method according to claim 4, wherein the temperature of the reduced pressure drying is 40 to 60 ℃.
9. A pharmaceutical composition comprising the crystalline form F of cycloastragenol of any one of claims 1-3.
10. Use of the crystalline form F of any one of claims 1-3 in the manufacture of a medicament for the treatment of a disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811644147.9A CN111378000A (en) | 2018-12-30 | 2018-12-30 | Cycloastragenol crystal form F and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811644147.9A CN111378000A (en) | 2018-12-30 | 2018-12-30 | Cycloastragenol crystal form F and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111378000A true CN111378000A (en) | 2020-07-07 |
Family
ID=71221132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811644147.9A Pending CN111378000A (en) | 2018-12-30 | 2018-12-30 | Cycloastragenol crystal form F and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111378000A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103880910A (en) * | 2014-03-19 | 2014-06-25 | 西南交通大学 | Preparation method and application of cycloastragenol |
| CN105734109A (en) * | 2016-02-02 | 2016-07-06 | 成都锦泰和医药化学技术有限公司 | Producing and refining method for high-purity cycloastragenol |
| CN106083979A (en) * | 2016-06-17 | 2016-11-09 | 浙江工业大学 | A kind of Cycloastragenol extract and preparation method thereof and purposes |
| CN107058445A (en) * | 2017-05-09 | 2017-08-18 | 北京化工大学 | It is a kind of to convert the method that Astragaloside IV prepares cycloastragenol using two step enzymatic isolation methods |
-
2018
- 2018-12-30 CN CN201811644147.9A patent/CN111378000A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103880910A (en) * | 2014-03-19 | 2014-06-25 | 西南交通大学 | Preparation method and application of cycloastragenol |
| CN105734109A (en) * | 2016-02-02 | 2016-07-06 | 成都锦泰和医药化学技术有限公司 | Producing and refining method for high-purity cycloastragenol |
| CN106083979A (en) * | 2016-06-17 | 2016-11-09 | 浙江工业大学 | A kind of Cycloastragenol extract and preparation method thereof and purposes |
| CN107058445A (en) * | 2017-05-09 | 2017-08-18 | 北京化工大学 | It is a kind of to convert the method that Astragaloside IV prepares cycloastragenol using two step enzymatic isolation methods |
Non-Patent Citations (3)
| Title |
|---|
| CHUN-YAN SHEN ET AL.: "Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: pharmacological mechanisms and implications for drug discovery", 《BRITISH JOURNAL OF PHARMACOLOGY》 * |
| 李齐激 等: "民族药芒萁的化学成分研究", 《中国药学杂志》 * |
| 章诗迪 等: "环黄芪醇的制备工艺及药理作用研究进展", 《中国新药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112142679B (en) | Gefitinib and vanilloid eutectic methanol solvate and preparation method thereof | |
| CN109503475B (en) | Isonicotinamide methylpyrazine derivative eutectic I | |
| CN109438371B (en) | Methylpyrazine derivative arginine hydrate | |
| CN111378003B (en) | Cycloastragenol crystal form G and preparation method thereof | |
| CN111378001A (en) | Cycloastragenol crystal form E and preparation method thereof | |
| CN111378004A (en) | Cycloastragenol crystal form D and preparation method thereof | |
| CN111378000A (en) | Cycloastragenol crystal form F and preparation method thereof | |
| CN110627792A (en) | Pentoxifylline compound | |
| CN111377999A (en) | Cycloastragenol crystal form B and preparation method thereof | |
| CN111377998A (en) | Cycloastragenol crystal form C and preparation method thereof | |
| CN113214207B (en) | Hesperetin and betaine eutectic A, preparation method, composition and application thereof | |
| CN109438372B (en) | Methyl pyrazine derivative methanol compound | |
| CN109369546B (en) | Methylpyrazine derivative theophylline hemihydrate | |
| CN111518040B (en) | Methylpyrazine derivative-piperazine eutectic | |
| CN114727994A (en) | Youtilon hemihydrate single crystal and preparation method and application thereof | |
| CN108129355B (en) | Alpha crystal form of leonurine hydrochloride and preparation method and application thereof | |
| CN111378002A (en) | Novel cycloastragenol crystal form A and preparation method thereof | |
| CN110845491B (en) | Ipratropium bromide crystal | |
| CN110845492B (en) | Ipratropium bromide monohydrate | |
| CN116023340A (en) | Nitrone oxazine crystal form, preparation method and application | |
| CN111518098B (en) | Methylpyrazine derivative theophylline dihydrate | |
| CN111574435B (en) | 4,4' -dipyridyl methylpyrazine derivative eutectic crystal | |
| CN113214206B (en) | Hesperetin and betaine eutectic substance B, preparation method, composition and application thereof | |
| CN115960108A (en) | Amorphous nafrafine hydrochloride and preparation method thereof | |
| CN117756798A (en) | New crystal of ipratropium bromide and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200710 Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi Applicant after: Lunan Pharmaceutical Group Corp. Address before: 273400 Shandong city of Linyi province Feixian County North Ring Road No. 1 Applicant before: SHANDONG NEWTIME PHARMACEUTICALS Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |